Form 4: Director Equity Grant at Fate Therapeutics

Matt Abernethy, a Director at Fate Therapeutics, received a grant of stock options.

Summary

• Matt Abernethy, a Director at Fate Therapeutics, was granted stock options on June 12, 2026.
• The grant consists of 87,900 stock options with an exercise price of $2.06 per share.
• These options are exercisable starting June 12, 2036, and expire on June 12, 2036.
• The options vest and become exercisable on the earlier of June 12, 2027, or the date of the 2027 Annual Meeting of Stockholders, contingent on continued service.
• This grant is part of the Issuer's Non-Employee Director Compensation Policy for annual equity grants.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director as part of a compensation policy, with no immediate financial impact or significant strategic news.

Positives

• Director equity grant aligns incentives between management and shareholders.
• The grant of 87,900 options provides potential upside for the director.
• The vesting schedule encourages continued service and commitment to the company.

Negatives

• The exercise price of $2.06 per share may be higher than the current market price, depending on the stock's trading performance.
• The long vesting period (up to June 12, 2027) means the director cannot immediately benefit from the options.

Risks

• The value of the stock options is subject to the future performance of Fate Therapeutics' stock price.
• If the company's stock price does not exceed the exercise price of $2.06, the options may expire worthless.
• Continued service is required for vesting, meaning any departure from the board would forfeit unvested options.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the director's continued service. The options become exercisable in stages, with full exercisability by June 12, 2036, or the 2027 Annual Meeting, whichever comes first, provided the director remains on the board.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and pharmaceutical sectors, aiming to align executive interests with long-term shareholder value. This grant at Fate Therapeutics is consistent with industry norms for compensating non-employee directors.

Corporate Governance

Related Party Transactions

• Grant of 87,900 stock options to Director Matt Abernethy.

Stakeholder Impact

• Shareholders: The grant aligns director incentives with shareholder interests, but dilutes ownership slightly upon exercise.
• Employees: No direct impact, but reflects company's compensation strategy.
• Creditors: No direct impact.

Next Steps

• Director Matt Abernethy must continue his service on the board for the options to vest.
• The options will become exercisable on or before June 12, 2027, or the 2027 Annual Meeting.
• The options expire on June 12, 2036.

Key Dates

Keywords

stock options, director compensation, equity grant, Fate Therapeutics, SEC Form 4, insider trading, vesting schedule